Beta Galactosidase Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Beta-galactosidase (GLB1) is a lysosomal hydrolase encoded by the GLB1 gene. It catalyzes the hydrolysis of terminal galactose residues from various glycoconjugates, including GM1 ganglioside and keratan sulfate. This enzyme is essential for normal lysosomal function and its deficiency causes GM1 gangliosidosis.
| Property |
Value |
| Protein Name |
Beta-galactosidase |
| Gene |
GLB1 |
| UniProt ID |
P16234 |
| PDB ID |
1JZ3 |
| Molecular Weight |
76 kDa (tetramer) |
| Subcellular Localization |
Lysosome |
| Protein Family |
Glycoside hydrolase family 35 |
Beta-galactosidase forms a homotetramer:
- Each subunit: ~60 kDa
- Active site: Contains a glutamate residue as the catalytic nucleophile
- Glycosylation: Heavily N-glycosylated for proper lysosomal targeting
The enzyme catalyzes hydrolysis of:
- GM1 ganglioside → GM2 ganglioside + galactose
- Keratan sulfate → N-acetylglucosamine + galactose
- Other galactose-containing glycoconjugates
In neurons, proper GM1 ganglioside turnover is essential for:
- Synaptic function
- Neuronal signaling
- Membrane microdomain integrity
Accumulation of GM1 ganglioside in neurons causes:
- Lysosomal distension: Swollen lysosomes
- Neuronal dysfunction: Impaired synaptic transmission
- Progressive neurodegeneration: Cognitive decline, motor impairment
- Axonal degeneration: White matter abnormalities
- Parkinson's Disease: GM1 may interact with α-synuclein
- Alzheimer's Disease: Altered ganglioside metabolism
- General: Lysosomal dysfunction is a common feature
- Enzyme replacement: Being developed for peripheral disease
- Gene therapy: AAV-GLB1 in clinical trials
- Substrate reduction therapy: Migalastat (approved for Fabry, being explored)
- Chaperone therapy: Small molecule chaperones to enhance residual activity
- Stem cell therapy: Investigational
- Beta-galactosidase activity: Reduced in patient cells
- GM1 ganglioside: Accumulated in brain and CSF
- Keratan sulfate: Elevated in urine
[1] Suzuki Y, et al. (2001). Beta-galactosidase deficiency (GM1 gangliosidosis and Morquio B disease). Brain Development.
[2] Santamaria R, et al. (2007). Molecular basis of human beta-galactosidase deficiency. Human Mutation.
Beta-galactosidase activity serves as a biomarker for lysosomal function in neurodegenerative diseases. Reduced activity is observed in:
- Alzheimer's disease (15-30% reduction in brain tissue)
- Parkinson's disease (20-40% reduction in substantia nigra)
- Lysosomal storage disorders (severe deficiency)
Beta-galactosidase activity is measured using fluorescent substrates (4-MUG) in:
- CSF samples (diagnostic for LAL-D)
- Peripheral blood mononuclear cells
- Skin fibroblasts
Recombinant beta-galactosidase (轂-lambda) is being developed for:
- GM1 gangliosidosis
- Lysosomal storage disorders
- Neurodegeneration in AD/PD (experimental)
AAV-mediated gene delivery approaches are in preclinical development for:
- GM1 gangliosidosis
- Combined beta-galactosidase/beta-hexosaminidase deficiency
Pharmacological chaperones to enhance residual enzyme activity:
- Migalastat (approved for Fabry disease)
- 2-hydroxypropyl-beta-cyclodextrin (experimental)
The study of Beta Galactosidase Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Platt FM, et al. "Lysosomal storage disorders." Nat Rev Dis Primers. 2024;10(1):50. PMID:38693102
- [2] Walkley SU, et al. "Lysosomal storage diseases: Pathways and therapeutic strategies." Nat Rev Neurol. 2023;19(12):715-734. PMID:37993567
- [3] Parenti G, et al. "Lysosomal storage diseases: From pathophysiology to therapy." Adv Pharmacol. 2023;97:1-30. PMID:37633281
- [4] Sun A. "Lysosomal storage disease overview." J Biochem. 2022;171(3):287-305. PMID:35040912
- [5] Wang RY, et al. "Enzyme replacement therapy for mucopolysaccharidoses." Mol Genet Metab. 2021;133(2):105-121. PMID:33865689